Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Non-invasive near-infrared light-controlled nano material for treating diabetes mellitus

A technology of fluorescent nanomaterials and inorganic nanomaterials, which is applied in the field of diabetes medical research, can solve problems such as the unknown effectiveness of diabetes treatment, and achieve the effect of getting rid of the shackles of optical fibers, avoiding influence, and avoiding side effects

Active Publication Date: 2020-10-30
SUZHOU UNIV
View PDF9 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the complexity of the in vivo environment of organisms, whether upconversion fluorescent nanomaterials are effective for the treatment of diabetes is still unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Non-invasive near-infrared light-controlled nano material for treating diabetes mellitus
  • Non-invasive near-infrared light-controlled nano material for treating diabetes mellitus
  • Non-invasive near-infrared light-controlled nano material for treating diabetes mellitus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Embodiment 1: the synthesis of UCNP-PEG-GA

[0056] 1. NaYF with core-shell structure 4 :Yb / Tm@NaYF 4 Synthesis of upconverting nanoparticles (UCNPs):

[0057] NaYF with core-shell structure 4 :Yb / Tm@NaYF 4 Upconverting nanoparticles were synthesized by a thermal solvent method.

[0058] First synthesize nuclear NaYF 4 :Yb / Tm: Weigh 0.695mmol YCl on a weighing balance 3 (135.78 mg), 0.30 mmol YbCl 3 (83.82mg) and 0.005mmol TmCl 3 (1.38 mg), was added to a 50 mL three-necked flask, followed by 12 mL of oleic acid and 15 mL of octadecene. After fixing the three-necked flask on the heating platform, pass nitrogen gas into the reaction device for 5 minutes to remove the air, then start to heat up, and keep the reaction system at 160°C for 0.5 hours under magnetic stirring to dissolve the reactants and remove the reaction system. excess oxygen and moisture. Turn off the heating, and wait for the reaction system to cool down to room temperature. At this time, the pr...

Embodiment 2

[0067] Embodiment 2: cell model and related research

[0068] HepG2 cells were purchased from ATCC, and HUVEC cells were a gift from Tang Zhongying Hematology Research Center. Cells were cultured in DMEM medium containing 10% FBS and 25 mM glucose at 37°C with 5% CO 2 in a humid environment.

[0069] In order to obtain the HepG2 cell model of insulin resistance, HepG2 cells were induced and cultured for 18 hours in DMEM low-glucose medium containing 18mM glucosamine (glucosamine, GlcN) and 5mM glucose, to obtain the HepG2 cell model of insulin resistance. Plasmid transfection was completed by jetPRIME (Polyplus) reagent. When the cells grew to 50% density, the plasmid CIBN-CAAX and mCherry-CRY2-iSH were added to the transfection buffer at a ratio of 1:1.2, vortexed for 5 seconds and then added to the transfection buffer. Transfection reagent (1 μg plasmid corresponds to 50 μL transfection buffer and 1 μL transfection reagent), put it into the cell culture medium after standi...

Embodiment 3

[0077] Example 3: HepG2 cell insulin resistance model and related research

[0078] Glucosamine (GlcN)-induced insulin resistance model of HepG2 cells was used to evaluate the effect of UMO in vitro. Figure 10 a-d are the results of cell immunofluorescence staining experiments, where Figure 10 a and b are the results of immunofluorescence staining of cells in the normal control group and the GlcN-induced group under the condition of NIR light off, respectively; Figure 10 c and d are the results of immunofluorescence staining of cells in the normal control group and GlcN-induced group under the condition of NIR light on, respectively. In the figure, different colors are used to represent the fluorescent signals of mCherry, DAPI, and p-AKT. It can be seen from the cell immunofluorescence staining experiment ( Figure 10 ), in the normal group ( Figure 10 c) and GlcN treatment group ( Figure 10 d) The fluorescence signal intensity of p-AKT after being irradiated by NIR wa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a non-invasive near-infrared light-controlled nano material for treating diabetes mellitus, and claims to protect the application of an up-conversion fluorescence nano material in preparation of a tool for treating diabetes mellitus. The up-conversion fluorescence nano material comprises a rare earth element doped inorganic nano material, a hepatocyte targeting molecule and a water-soluble polymer. The invention discloses a new application of the non-invasive up-conversion fluorescent nano material. An invasive optical fiber does not need to be implanted into an animalthrough an operation during diabetes treatment, near-infrared light with high tissue penetrability is used for exciting an up-conversion nano material in a living body, and light in the near-infraredband is converted into visible light through the up-conversion material so that photosensitive protein is activated, and glucose metabolism related signal pathways in cells are remotely regulated andcontrolled without relying on insulin under the condition of high time-space resolution, glycogen synthesis is promoted, glycogenesis is inhibited, and the blood glucose level is reduced.

Description

technical field [0001] The invention relates to the field of medical research on diabetes, in particular to a non-invasive near-infrared light-controlled nanometer material for treating diabetes. Background technique [0002] Optogenetics technology is a brand-new technology produced by combining genetics technology and light control regulation technology. In the past ten years, optogenetics has made great progress in many research fields, including frontier fields such as neuroscience, tumor therapy, signaling pathway research, and exosome engineering. In order to enrich the toolbox of optogenetics research, scientists have developed light-sensitive protein components including rhodopsin, retinoid, phytochrome, cryptochrome and so on. Optogenetic technology is to genetically modify the target cells, implant the corresponding light-sensitive proteins, and precisely activate the light-sensitive proteins in the target cells in the target area by means of light control to regu...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K41/00A61K47/55A61K47/60A61K47/69A61P3/10B82Y5/00B82Y20/00B82Y40/00
CPCA61K41/0038A61K47/554A61K47/60A61P3/10A61K47/6923B82Y5/00B82Y20/00B82Y40/00A61K47/6925B82Y30/00
Inventor 刘坚严俊
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com